| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | THSD7A |
| Uniprot No | Q9UPZ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于THSD7A重组蛋白的3篇代表性文献及其摘要内容：
1. **文献名称**：*THSD7A Positivity is Associated with Malignancy in Membranous Nephropathy*
**作者**：Hoxha E. et al.
**摘要**：该研究通过检测THSD7A重组蛋白在膜性肾病患者中的表达，发现THSD7A自身抗体与恶性肿瘤的潜在关联，提示其可能作为肿瘤相关膜性肾病的生物标志物。
2. **文献名称**：*Recombinant THSD7A Identifies Pathogenic Autoantibodies in Primary Membranous Nephropathy*
**作者**：Tomas N.M. et al.
**摘要**：研究利用重组THSD7A蛋白开发了特异性检测方法，证实其在诊断THSD7A相关膜性肾病中的高敏感性和特异性，为临床提供无创诊断工具。
3. **文献名称**：*THSD7A-Targeted Autoantibodies Induce Podocyte Injury via β1 Integrin Signaling*
**作者**：Seitz-Polski B. et al.
**摘要**：通过体外实验发现，抗THSD7A自身抗体通过激活β1整合素信号通路导致足细胞损伤，揭示了THSD7A在膜性肾病病理机制中的关键作用。
以上文献均聚焦于THSD7A重组蛋白在疾病诊断、致病机制及临床关联中的应用。
THSD7A (thrombospondin type-1 domain-containing protein 7A) is a transmembrane glycoprotein primarily expressed in podocytes, specialized cells critical for maintaining the glomerular filtration barrier in the kidneys. It gained prominence in nephrology following its identification as a target antigen in a subset of patients with primary membranous nephropathy (MN), an autoimmune kidney disorder characterized by autoantibody-mediated podocyte injury. Approximately 10-20% of primary MN cases are linked to circulating anti-THSD7A antibodies, establishing THSD7A as a disease-specific biomarker.
Structurally, THSD7A contains multiple thrombospondin type-1 (TSP-1) domains, which are known to mediate protein-protein interactions and cellular adhesion. Its physiological role remains incompletely understood, though studies suggest involvement in angiogenesis, neuronal development, and podocyte signaling. The recombinant form of THSD7A is typically produced in mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications, particularly glycosylation patterns critical for antigenic recognition.
Clinically, recombinant THSD7A proteins serve as essential tools for diagnosing THSD7A-associated MN through antibody detection assays. Research applications include investigating antigen-antibody interactions, dissecting molecular pathways in podocyte injury, and developing targeted therapeutic strategies. Recent studies also explore its potential extrarenal expression patterns and implications in cancer biology. The development of recombinant THSD7A has significantly advanced our understanding of autoimmune kidney diseases while highlighting the need for further investigation into its native biological functions and therapeutic targeting opportunities.
×
